Overview
Lipoprotein(a) — said "L-P-little-a" — is an LDL-like particle with an extra protein attached. Its level is set almost entirely by genetics, stays roughly stable across your adult life, and is barely influenced by diet or exercise. It also raises cardiovascular risk independently of everything else on your lipid panel.
Which makes it unusual among biomarkers: it is worth measuring once, and generally not worth measuring again.
| Most lipid markers | Lp(a) | |
|---|---|---|
| What sets the level | Diet, weight, activity, genetics, medication | Predominantly genetics — roughly 80–90% heritable |
| Does it change? | Yes, meaningfully, with lifestyle and treatment | Very little across adult life |
| How often to test | Periodically, to track | Once is usually enough |
| What it changes | Ongoing management | How aggressively everything else gets managed |
| How commonly measured | Routinely | Rarely — most people never have it checked |
The practical point: you cannot change it much, but knowing it changes the intensity with which the modifiable risks around it get treated.
What the particle actually is
Take an LDL particle and attach an additional protein — apolipoprotein(a) — and you have Lp(a). That extra protein is what makes it behave differently.
It appears to contribute to risk through more than one route: like LDL it can enter and be retained in the artery wall, and it also carries pro-inflammatory properties and structurally resembles a protein involved in clot breakdown, which may interfere with that process. The mechanisms are still being worked out. The association with cardiovascular events, and specifically with aortic valve narrowing, is well established.
Roughly one in five people worldwide carries a level considered elevated. Most of them do not know.
Why it is so rarely measured
Historically, for a defensible reason: there was nothing specific to do about it. Standard lipid-lowering treatment does not lower Lp(a) much, and diet and exercise barely touch it. A test that identified an unmodifiable risk factor with no targeted treatment was a hard sell.
Two things have shifted that. First, knowing your Lp(a) genuinely changes how everything else gets managed — if you carry a high level, the case for controlling the risks you can modify becomes considerably stronger. Second, therapies specifically targeting Lp(a) have been in clinical development, and while none should be described as established practice today, the picture is not static.
What the numbers look like
Results are reported either in mg/dL or in nmol/L, and the two are not straightforwardly interchangeable — the relationship depends on particle size, which varies between people. If you are comparing results, check the units first, because this is a common source of confusion.
Thresholds for "elevated" are commonly cited around 50 mg/dL or 125 nmol/L, though the exact cut-off varies between guidelines and assays. Risk rises continuously rather than switching on at a threshold, so a value just below a cut-off is not meaningfully different from one just above.
Levels also differ substantially between ancestral populations, which matters for interpretation.
What a high result should change
Not panic, and not a specific Lp(a) treatment. What it should change is the intensity of everything else.
If you carry a high Lp(a), the argument for tight control of the modifiable risks becomes stronger — blood pressure, ApoB and LDL, smoking, insulin resistance, body composition. You cannot lower the inherited risk much, so you lower the total by working harder on the parts that will move.
It is also family information. Lp(a) is inherited, so a high result in you raises the question for siblings, parents and children. Cascade testing of first-degree relatives is a reasonable conversation, and it is one of the few lipid findings where telling your family genuinely matters.
And where the overall picture warrants it, it strengthens the case for imaging — a coronary calcium score to establish whether plaque is already present. That is a referral rather than something we can perform.
What it does not mean
A high Lp(a) is a risk factor, not a diagnosis and not a prediction. Plenty of people with elevated levels never have an event, and the number is one input into an overall risk picture rather than the whole of it.
It also does not mean standard treatment is pointless. Lowering ApoB and LDL still reduces risk in someone with high Lp(a) — arguably it matters more, not less.
Frequently asked questions
How often should I test it? Generally once in adult life. It is stable enough that repeat testing rarely adds information, unless something specific changes the clinical question.
Can I lower it with diet or exercise? Not meaningfully. This is genuinely different from the rest of the lipid panel, and it is worth knowing so you do not conclude your efforts are failing.
Does it run in families? Yes — that is the defining feature. A high result is a reason to raise it with first-degree relatives.
Is it the same as LDL? Related but distinct. It is an LDL-like particle with an extra protein, and it is not captured by a standard LDL-C measurement. It does contribute to ApoB, which is one reason the two are worth reading together.
Should everyone get this tested? Guidance varies, and there is a reasonable argument for at least once in adult life given it is a one-off test with family implications. It is particularly worth doing where there is premature cardiovascular disease in the family, or a personal event that the standard risk factors did not explain.
Where this fits in your plan
Lp(a) is the rare marker where one test does the job and the result reframes everything around it rather than being managed itself.
If cardiovascular risk is part of what brought you here — a family history, an unexplained event in a relative, or simply wanting a fuller picture at 50 — it belongs on the panel alongside ApoB and the standard lipids, measured once and then referred back to.
We measure first. Then we act.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
